Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioventusFRA:4B8 -8.78%45 FCF Margin % is 12.35% as of Jun. 2026, which is 122% above its 10-year median of 5.56. GuruFocus rates FRA:4B8 with a GF Score™ of 45/100 and a GF Value™ of €6.52 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 814 Medical Devices & Instruments companies, Bioventus ranks better than 86.61% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Bioventus's Free Cash Flow for the
three
months ended in Jun. 2026 was €16.4 Mil. Bioventus's Revenue for the
three
months ended in Jun. 2026 was €133.0 Mil. Therefore, Bioventus's FCF Margin % for the quarter that ended in Jun. 2026 was 12.35%.
The historical rank and industry rank for Bioventus's FCF Margin % or its related term are showing as below:
FRA:4B8'
s FCF Margin % Range Over the Past 10 Years
Min: -2.93 Med: 5.56 Max: 16.16
Current: 16.16
During the past 11 years, the highest FCF Margin % of Bioventus was 16.16%. The lowest was -2.93%. And the median was 5.56%.
FRA:4B8's FCF Margin % is ranked better than 86.61% of 814
companies
in the Medical Devices & Instruments industry
Industry Median: -0.815
vs FRA:4B8: 16.16
The historical data trend for Bioventus's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:4B8 vs AVR, SIBN, INMD: FCF Margin % Comparison
For the Medical Devices subindustry, Bioventus's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioventus FCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bioventus's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Bioventus's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioventus (FRA:4B8) has a FCF Margin % of 12.35% as of Jun. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Bioventus and its competitors. This is 122% above median its historical median of 5.56. According to the industry distribution chart, Bioventus ranks #109 out of 814 companies in the Medical Devices & Instruments industry, placing it in the top 13.4%.
Is Bioventus' FCF Margin % too high?
Bioventus' current FCF Margin % of 12.35% is 122% above median its 10-year median of 5.56. Based on the distribution chart, Bioventus ranks #109 out of 814 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Bioventus has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bioventus' FCF Margin % compare to AVR and SIBN?
According to the Medical Devices & Instruments industry distribution chart, Bioventus ranks #109 out of 814 companies for FCF Margin %. This places Bioventus in the top 13% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Bioventus and its competitors. Bioventus's current FCF Margin % is 12.35%, which is 122% above median its own 10-year median of 5.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioventus stock overvalued right now?
Based on GuruFocus' analysis, Bioventus (FRA:4B8) is currently considered Significantly Overvalued. The stock's GF Value™ is €6.52, compared to a current price of €11.95 — trading 83.3% above its estimated fair value. The current FCF Margin % is 12.35%, which is 122% above median its 10-year median of 5.56. Bioventus' overall GF Score™ is 45/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Bioventus (FRA:4B8), the current FCF Margin % is 12.35% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bioventus (FRA:4B8) Overvalued in 2026?
Based on GuruFocus' analysis, Bioventus stock appears to be overvalued.
The current stock price of €11.95 is trading 83.3% above its estimated GF Value™ of €6.52.
GuruFocus considers Bioventus to be Significantly Overvalued.
Key valuation signals for FRA:4B8:
FCF Margin %: 12.35% (122% above median its 10-year median of 5.56)
GF Value™: €6.52 vs. price of €11.95 (83.3% above fair value)
No single metric tells the full story. See the FRA:4B8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioventus Inc is a medical device company focused on developing and commercializing products to relieve pain and address musculoskeletal conditions. The company operates through two reporting segments, U.S. and International, and its product portfolio is organized into three main business areas: Pain Treatments, Surgical Solutions, and Restorative Therapies, offering products such as hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, bone graft substitutes, and ultrasound-based fracture healing therapies.
45GF Score
Get the complete analysis for FRA:4B8
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4B8 has been successfully added to your 
